fashion -WSS

fashion

author：focus 2025-10-06 15:36:34 Page View：64

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.

RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.

Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Shionogi licenses Pompe disease therapy from Maze Therapeutics
Next article： Trump demands the U.S. pay no more for drugs than other countries … again

explore

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

Making AI in medicine accessible to smaller, and rural hospitals

NorthCountryHealthCareInKingman,Ariz.,awindsweptcityof35,000attheeasternedgeoftheMojavedesert,datasc

In Memoriam: Notable people who died in 2023

1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel

Use wet bulb globe temperature, not heat index, to protect workers

FarmworkerspickinggrapesinCalifornia'sCentralValleyduringthe2021heatwave.FREDERICJ.BROWN/AFPviaGetty